Complement factor I deficiency: a not so rare immune defect. Characterization of new mutations and the first large gene deletion
暂无分享,去创建一个
P. Soler-Palacín | M. López-Trascasa | F. Leturcq | J. Kaplan | J. Chelly | E. Le Rumeur | A. Nicolas | F. Barloy-Hubler | R. Yaou | C. Cámara | Céline Lucchetti-Miganeh | A. López-Lera | P. Nozal | María Alba-Domínguez | S. Garrido | J. Melero | Ignacio González-Granado | Josefa Melero
[1] B. Paul Morgan,et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome , 2007, Proceedings of the National Academy of Sciences.
[2] N. Bresolin,et al. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. , 1994, Brain : a journal of neurology.
[3] S. Winder,et al. ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site. , 2007, The Biochemical journal.
[4] A. Fischer,et al. Primary immunodeficiencies: 2009 update. , 2009, The Journal of allergy and clinical immunology.
[5] M. Koenig,et al. Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.
[6] H. Ochs,et al. The role of complement in the induction of antibody responses. , 1983, Clinical and experimental immunology.
[7] J. Mendell,et al. Mutation rates in the dystrophin gene: A hotspot of mutation at a CpG dinucleotide , 2005, Human mutation.
[8] M. López-Trascasa,et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. , 2009, Blood.
[9] Peer Bork,et al. SMART 6: recent updates and new developments , 2008, Nucleic Acids Res..
[10] W. King,et al. Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. , 1993, Human molecular genetics.
[11] A. Monaco,et al. Distal transcript of the dystrophin gene initiated from an alternative first exon and encoding a 75-kDa protein widely distributed in nonmuscle tissues. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] A. Blom,et al. Complement factor I in health and disease. , 2011, Molecular immunology.
[13] N. Hattori,et al. Undetectable dystrophin can still result in a relatively benign phenotype of dystrophinopathy , 1999, Neuromuscular Disorders.
[14] Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database , 2012, Orphanet Journal of Rare Diseases.
[15] A. Lupas. Coiled coils: new structures and new functions. , 1996, Trends in biochemical sciences.
[16] W. Fridman,et al. Complement Mutation‐Associated De Novo Thrombotic Microangiopathy Following Kidney Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[17] L. Kunkel,et al. An alternative dystrophin transcript specific to peripheral nerve , 1993, Nature Genetics.
[18] Johan T den Dunnen,et al. Local dystrophin restoration with antisense oligonucleotide PRO051. , 2007, The New England journal of medicine.
[19] A. Monaco,et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.
[20] Manfred J. Sippl,et al. Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..
[21] Andrew P. Weir,et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. , 2002, Physiological reviews.
[22] K. Buetow,et al. Mapping of the human complement factor I gene to 4q25. , 1989, Genomics.
[23] Yang Zhang,et al. I-TASSER server for protein 3D structure prediction , 2008, BMC Bioinformatics.
[24] S. Winder,et al. Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. , 2006, Trends in cell biology.
[25] S. Pandya,et al. Mutation Analysis in a Population-Based Cohort of Boys With Duchenne or Becker Muscular Dystrophy , 2009, Journal of child neurology.
[26] L. Morandi,et al. Dystrophin characterization in BMD patients: correlation of abnormal protein with clinical phenotype , 1995, Journal of the Neurological Sciences.
[27] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[28] M. Bobrow,et al. Dystrophins in vertebrates and invertebrates. , 1998, Human molecular genetics.
[29] U. Rother. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. , 1982, Journal of immunological methods.
[30] M. López-Trascasa,et al. Molecular characterization of Complement Factor I deficiency in two Spanish families. , 2008, Molecular immunology.
[31] M. Sippl. Recognition of errors in three‐dimensional structures of proteins , 1993, Proteins.
[32] P. Sánchez-Corral,et al. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome , 2010, British journal of haematology.
[33] F. Salvatore,et al. Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity. , 2005, Annals of human genetics.
[34] Xin Huang,et al. Structure of a WW domain containing fragment of dystrophin in complex with β-dystroglycan , 2000, Nature Structural Biology.
[35] C. Licht,et al. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis , 2009, Thrombosis and Haemostasis.
[36] G. van Ommen,et al. Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading‐frame rule , 2006, Muscle & nerve.
[37] J. Bourke,et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.
[38] D. Eisenberg,et al. Assessment of protein models with three-dimensional profiles , 1992, Nature.
[39] W. Fridman,et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. , 2005, Journal of the American Society of Nephrology : JASN.
[40] A. Monaco,et al. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.
[41] J. Burgunder,et al. Becker muscular dystrophy with marked divergence between clinical and molecular genetic findings: case series. , 2006, Swiss medical weekly.
[42] C. Gilissen,et al. Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy , 2010, PloS one.
[43] N. Menhart. Hybrid spectrin type repeats produced by exon-skipping in dystrophin. , 2006, Biochimica et biophysica acta.
[44] M. Kirschfink,et al. Recurrent infections in partial complement factor I deficiency: evaluation of three generations of a Brazilian family , 2006, Clinical and experimental immunology.
[45] J. T. Dunnen,et al. Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort , 2005, American journal of medical genetics. Part A.
[46] Andrea O'Neill,et al. Specific interaction of the actin-binding domain of dystrophin with intermediate filaments containing keratin 19. , 2005, Molecular biology of the cell.
[47] Anna Carla Turconi,et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up , 2011, Journal of Neurology.
[48] D. Eisenberg,et al. A method to identify protein sequences that fold into a known three-dimensional structure. , 1991, Science.
[49] M. Oppermann,et al. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[50] J. T. Dunnen,et al. Copy number variation in the genome; the human DMD gene as an example , 2006, Cytogenetic and Genome Research.
[51] A. Blom,et al. Genetic, molecular and functional analyses of complement factor I deficiency , 2009, European journal of immunology.
[52] D. Fearon. Purification of C3b inactivator and demonstration of its two polypeptide chain structure. , 1977, Journal of immunology.
[53] Christophe Béroud,et al. Genotype–phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD–DMD database: a model of nationwide knowledgebase , 2009, Human mutation.
[54] I. Fokkema,et al. LOVD: Easy creation of a locus‐specific sequence variation database using an “LSDB‐in‐a‐box” approach , 2005, Human mutation.
[55] T. Partridge,et al. Optimizing exon skipping therapies for DMD. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[56] L. Kunkel,et al. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. , 1995, Human molecular genetics.
[57] H Sugita,et al. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.
[58] D. Parry,et al. Fifty years of coiled-coils and alpha-helical bundles: a close relationship between sequence and structure. , 2008, Journal of structural biology.
[59] M. Thambyayah,et al. Prevalence and incidence of Becker muscular dystrophy , 1991, The Lancet.
[60] K. Bushby,et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. , 2011, Brain : a journal of neurology.
[61] V. Bennett,et al. An Ankyrin-Based Mechanism for Functional Organization of Dystrophin and Dystroglycan , 2008, Cell.
[62] L. Kunkel,et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.
[63] O. Horaitis,et al. Human Genome Variation Society , 2006, Springer Reference Medizin.
[64] N. Plant,et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? , 2012, Clinical journal of the American Society of Nephrology : CJASN.
[65] Thierry Soussi,et al. UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.
[66] E. Birney,et al. Pfam: the protein families database , 2013, Nucleic Acids Res..
[67] L. Ségalat. Dystrophin and functionally related proteins in the nematode Caenorhabditis elegans , 2002, Neuromuscular Disorders.
[68] G. van Ommen,et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.
[69] P. Ray,et al. A novel dystrophin isoform is required for normal retinal electrophysiology. , 1995, Human molecular genetics.
[70] S. Thiel,et al. Disease-causing mutations in genes of the complement system. , 2011, American journal of human genetics.
[71] L. Kunkel,et al. Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[72] H. Zeitz,et al. Complement factor I deficiency with recurrent aseptic meningitis. , 1993, Archives of internal medicine.
[73] Yang Zhang,et al. I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.
[74] E. Bertini,et al. Transcriptional behavior of DMD gene duplications in DMD/BMD males , 2009, Human mutation.
[75] R. Dwek,et al. Human complement factor I glycosylation: structural and functional characterisation of the N-linked oligosaccharides. , 2006, Biochimica et biophysica acta.
[76] K. Davies,et al. ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. , 2004, Human molecular genetics.
[77] M. Saraste,et al. Structural comparisons of calponin homology domains: implications for actin binding. , 1998, Structure.
[78] J. Ervasti,et al. A Cluster of Basic Repeats in the Dystrophin Rod Domain Binds F-actin through an Electrostatic Interaction* , 1998, The Journal of Biological Chemistry.
[79] H. Ochs,et al. Primary immunodeficiency diseases : a molecular and genetic approach , 2013 .
[80] F. Leturcq,et al. Clinical Heterogeneity of Duchenne Muscular Dystrophy (DMD): Definition of Sub-Phenotypes and Predictive Criteria by Long-Term Follow-Up , 2009, PloS one.
[81] V. Frémeaux-Bacchi,et al. Atypical hemolytic uremic syndrome , 2011, Orphanet journal of rare diseases.
[82] F. Rivier,et al. Mutation spectrum leading to an attenuated phenotype in dystrophinopathies , 2005, European Journal of Human Genetics.
[83] O. Delalande,et al. Computational Study of the Human Dystrophin Repeats: Interaction Properties and Molecular Dynamics , 2011, PloS one.
[84] H. Sweeney,et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[85] Eric P. Hoffman,et al. Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.
[86] Bernard Dan,et al. Pathophysiology of duchenne muscular dystrophy: current hypotheses. , 2007, Pediatric neurology.
[87] J. Chamberlain,et al. Interactions between dystrophin and the sarcolemma membrane. , 1997, Society of General Physiologists series.
[88] Narmada Thanki,et al. CDD: specific functional annotation with the Conserved Domain Database , 2008, Nucleic Acids Res..
[89] Thomas W Prior,et al. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. , 2005, The Journal of molecular diagnostics : JMD.
[90] B. Nilsson,et al. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). , 2008, Molecular immunology.
[91] S. Hardy,et al. Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. , 2009, Journal of molecular biology.
[92] P. Zipfel,et al. Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.
[93] T. Gibson,et al. Dystrophin and utrophin: the missing links! , 1995, FEBS letters.
[94] P. Roversi,et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms , 2011, Proceedings of the National Academy of Sciences.
[95] Francesco Saverio Tedesco,et al. Complement in human diseases: Lessons from complement deficiencies. , 2009, Molecular immunology.
[96] W. Fridman,et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome , 2004, Journal of Medical Genetics.
[97] Y. Hayashi,et al. The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b. , 2010, Biochemical and biophysical research communications.
[98] G. Puca,et al. Novel small mutations along the DMD/BMD gene associated with different phenotypes. , 1994, Human molecular genetics.
[99] G. Bruns,et al. Human complement factor I: analysis of cDNA-derived primary structure and assignment of its gene to chromosome 4. , 1987, The Journal of biological chemistry.
[100] D. Duan,et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. , 2009, The Journal of clinical investigation.
[101] J. Fajkus,et al. Novel dystrophin mutations revealed by analysis of dystrophin mRNA: alternative splicing suppresses the phenotypic effect of a nonsense mutation , 2001, Neuromuscular Disorders.
[102] K. Campbell,et al. Association of dystrophin and an integral membrane glycoprotein , 1989, Nature.
[103] F. Gudat,et al. Glomerulonephritis in a patient with complement factor I deficiency. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[104] A. Pestronk,et al. Analysis of Dystrophin Deletion Mutations Predicts Age of Cardiomyopathy Onset in Becker Muscular Dystrophy , 2009, Circulation. Cardiovascular genetics.
[105] Y. Shoenfeld,et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation , 1998, Immunologic research.
[106] L. Isaac,et al. Molecular characterization of homozygous hereditary factor I deficiency , 2003, Clinical and experimental immunology.
[107] S. Winder,et al. Dystrophin: more than just the sum of its parts. , 2010, Biochimica et biophysica acta.
[108] M. Walport,et al. The molecular basis of hereditary complement factor I deficiency. , 1996, The Journal of clinical investigation.
[109] I. Graham,et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study , 2009, The Lancet Neurology.
[110] C. Bell,et al. Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy , 2007, Journal of Medical Genetics.
[111] Dongsheng Duan,et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy , 2002, Nature Medicine.
[112] Julie Donaghey,et al. Deregulated Protein Kinase A Signaling and Myospryn Expression in Muscular Dystrophy* , 2008, Journal of Biological Chemistry.
[113] N. Keep,et al. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. , 2000, Structure.
[114] L. Truedsson,et al. Complement factor I deficiency associated with recurrent infections, vasculitis and immune complex glomerulonephritis , 2005, Scandinavian journal of infectious diseases.
[115] F. Muntoni,et al. Large in-frame deletions of the rod-shaped domain of the dystrophin gene resulting in severe phenotype. , 2003, The Israel Medical Association journal : IMAJ.
[116] Y. Berwald‐Netter,et al. Dystrophin gene transcribed from different promoters in neuronal and glial cells , 1990, Nature.
[117] C. Ponting,et al. Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex , 2000, Current Biology.
[118] A. Jauch,et al. MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls , 2005, Neurogenetics.
[119] K. Davies,et al. Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with β-dystroglycan , 2007, The Journal of cell biology.
[120] Christophe Béroud,et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy , 2007, Human mutation.
[121] L. Kunkel,et al. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. , 1990, The Journal of biological chemistry.
[122] M. López-Trascasa,et al. Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation. , 2001, Archives of neurology.
[123] H. Colten,et al. Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. , 1984, The Journal of biological chemistry.
[124] P. Barlow,et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. , 2010, Blood.
[125] K. Campbell,et al. Interactions of intermediate filament protein synemin with dystrophin and utrophin. , 2006, Biochemical and biophysical research communications.
[126] Livija Medne,et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.
[127] M. Taniike,et al. Molecular study of duchenne and Becker muscular dystrophies in Japanese , 1991, Journal of Inherited Metabolic Disease.
[128] K. Campbell. Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage , 1995, Cell.
[129] C. Carter. Mendelian Inheritance in Man , 1967 .